Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 17, 2009

imaGenes Becomes BioTrove’s OpenArray Service Provider

  • imaGenes will complement its offerings with BioTrove’s OpenArray® platform, a nanoliter real-time qPCR system that allows for about 9,000 assays simultaneously. imaGenes is BioTrove’s first OpenArray service provider for real-time qPCR analysis outside the U.S. “We chose imaGenes for their extensive experience in microarray and next-generation sequencing services,” says Derek Potter, BioTrove’s European director.

    The high-throughput OpenArray platform delivers superior performance to comparative qPCR systems in a much easier to use format, according to the firms. The technology enables gene-expression profiling, miRNA-profiling analyses, and biomarker studies to be completed in days instead of weeks and at a much lower price, they add.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »